WO1996038556A3 - Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse - Google Patents

Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse Download PDF

Info

Publication number
WO1996038556A3
WO1996038556A3 PCT/FR1996/000802 FR9600802W WO9638556A3 WO 1996038556 A3 WO1996038556 A3 WO 1996038556A3 FR 9600802 W FR9600802 W FR 9600802W WO 9638556 A3 WO9638556 A3 WO 9638556A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
cancer
acid sequences
gene therapy
deltap62
Prior art date
Application number
PCT/FR1996/000802
Other languages
English (en)
Other versions
WO1996038556A2 (fr
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Fabien Schweighoffer
Bruno Tocque
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Fabien Schweighoffer, Bruno Tocque filed Critical Rhone Poulenc Rorer Sa
Priority to US08/952,899 priority Critical patent/US6544948B1/en
Priority to BR9608632A priority patent/BR9608632A/pt
Priority to AU61291/96A priority patent/AU718889B2/en
Priority to JP8536252A priority patent/JPH11506325A/ja
Priority to SK1613-97A priority patent/SK283071B6/sk
Priority to EP96918728A priority patent/EP0828832A2/fr
Publication of WO1996038556A2 publication Critical patent/WO1996038556A2/fr
Publication of WO1996038556A3 publication Critical patent/WO1996038556A3/fr
Priority to MXPA/A/1997/008877A priority patent/MXPA97008877A/xx
Priority to NO975409A priority patent/NO975409D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau polypeptide désigné ΔP62, ou ΔSam68, ses variants, les séquences nucléiques correspondantes, et leurs utilisations, notamment en thérapie génique anti-cancéreuse.
PCT/FR1996/000802 1995-06-01 1996-05-29 Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse WO1996038556A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US08/952,899 US6544948B1 (en) 1995-06-01 1996-05-29 ΔP62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer
BR9608632A BR9608632A (pt) 1995-06-01 1996-05-29 Derivado de p62 polipeptídeo ap62 polipeptídio p62-c ácido nucléico cassete de expressão vetor retrovírus recombinante defectivo adenovírus recombinante defectivo composição farmacêutica e utilização de um ácido nucléico
AU61291/96A AU718889B2 (en) 1995-06-01 1996-05-29 deltaP62, its variants, nucleic acid sequences and their uses
JP8536252A JPH11506325A (ja) 1995-06-01 1996-05-29 Δｐ６２、その変異体、核酸配列及びこれらの使用
SK1613-97A SK283071B6 (sk) 1995-06-01 1996-05-29 Proteín Deltap62, jeho varianty, nukleotidové sekvencie a ich využitie
EP96918728A EP0828832A2 (fr) 1995-06-01 1996-05-29 $g(D)P62, SES VARIANTS, SEQUENCES D'ACIDES NUCLEIQUES LES CODANT, ET LEURS UTILISATIONS EN THERAPIE GENIQUE ANTI-CANCEREUSE
MXPA/A/1997/008877A MXPA97008877A (en) 1995-06-01 1997-11-18 P62, its variants, the nucleic acid sequences that code them, and its use in anti-cancer gene therapy
NO975409A NO975409D0 (no) 1995-06-01 1997-11-25 <Delta>P62, varianter derav, nukleinsekvenser og deres anvendelse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR95/06533 1995-06-01
FR9506533A FR2734826B1 (fr) 1995-06-01 1995-06-01 Deltap62, ses variants, sequences nucleiques et leurs utilisations

Publications (2)

Publication Number Publication Date
WO1996038556A2 WO1996038556A2 (fr) 1996-12-05
WO1996038556A3 true WO1996038556A3 (fr) 1997-01-09

Family

ID=9479588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1996/000802 WO1996038556A2 (fr) 1995-06-01 1996-05-29 Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse

Country Status (15)

Country Link
US (1) US6544948B1 (fr)
EP (1) EP0828832A2 (fr)
JP (1) JPH11506325A (fr)
KR (1) KR19990022193A (fr)
AU (1) AU718889B2 (fr)
BR (1) BR9608632A (fr)
CA (1) CA2219861A1 (fr)
CZ (1) CZ291533B6 (fr)
FR (1) FR2734826B1 (fr)
HU (1) HUP9901346A3 (fr)
IL (1) IL118493A0 (fr)
NO (1) NO975409D0 (fr)
SK (1) SK283071B6 (fr)
WO (1) WO1996038556A2 (fr)
ZA (1) ZA964392B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2493300A (en) * 1999-01-06 2000-07-24 Regents Of The University Of California, The Modulation of hiv replication using sam68
US7479368B2 (en) * 2001-07-30 2009-01-20 G.R.M.O. (Groupe De Recherche En Maladies Osseuses) Inc. Method for detecting subjects having Paget's disease of bone
SG2014008411A (en) * 2011-08-08 2014-03-28 Curelab Oncology Inc Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
WO2021231652A1 (fr) * 2020-05-14 2021-11-18 Curelab Oncology, Inc. Utilisation du plasmide p62 pour traiter ou réduire la gravité d'infections à coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020794A1 (fr) * 1991-05-17 1992-11-26 Cetus Oncology Corporation Purification et clonage du polypeptide p62
WO1995002697A1 (fr) * 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020794A1 (fr) * 1991-05-17 1992-11-26 Cetus Oncology Corporation Purification et clonage du polypeptide p62
WO1995002697A1 (fr) * 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
RICHARD, S. ET AL.: "Association of p62, a multifunctional SH2- and SH3-domain-binding protein, with src family tyrosine kinases, Grb2, and phospholipase C-gamma-1.", MOLECULAR AND CELLULAR BIOLOGY 15 (1). 1995. 186-197. ISSN: 0270-7306, XP000562643 *
SIOMI, H. ET AL.: "Essential role for KH domains in RNA binding: impaired RNA binding by a mutation in the KH domain of FMR1 that causes fragile X syndrome", CELL, vol. 77, 8 April 1994 (1994-04-08), NA US, pages 33 - 39, XP002018362 *
WANG, L. ET AL.: "P62 association with RNA is regulated by tyrosine phosphorylation.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 FEB 3) 270 (5) 2010-3, XP002018361 *
WISNIEWSKI, D. ET AL.: "A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.", LEUKEMIA, (1994 APR) 8 (4) 688-93, XP000562646 *
WONG, G. ET AL.: "Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62.", CELL, (1992 MAY 1) 69 (3) 551-8, XP002018363 *

Also Published As

Publication number Publication date
HUP9901346A3 (en) 2000-10-30
KR19990022193A (ko) 1999-03-25
FR2734826A1 (fr) 1996-12-06
NO975409L (no) 1997-11-25
US6544948B1 (en) 2003-04-08
NO975409D0 (no) 1997-11-25
SK283071B6 (sk) 2003-02-04
SK161397A3 (en) 1998-07-08
ZA964392B (en) 1996-12-09
EP0828832A2 (fr) 1998-03-18
CZ291533B6 (cs) 2003-03-12
IL118493A0 (en) 1996-09-12
HUP9901346A2 (hu) 1999-08-30
FR2734826B1 (fr) 1997-07-04
CA2219861A1 (fr) 1996-12-05
AU6129196A (en) 1996-12-18
WO1996038556A2 (fr) 1996-12-05
MX9708877A (es) 1998-03-31
BR9608632A (pt) 1999-05-04
JPH11506325A (ja) 1999-06-08
CZ375997A3 (cs) 1998-02-18
AU718889B2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
WO1997007198A3 (fr) Sequences d&#39;adn et proteines secretees codees par celles-ci
AU3274995A (en) Fibrin-binding peptides, dna coding therefor and uses thereof
EP0679716A4 (fr) Signature genique.
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
ZA972439B (en) Amino acid fermentation processes.
AU2681497A (en) Novel agouti-related gene
WO1994029446A3 (fr) Proteines intracellulaires de liaison (pil) et leurs utilisations
WO1998042827A3 (fr) Gene codant pour un oxalate decarboxylase isole a partir d&#39;aspergillus phoenices
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
EP0759470A3 (fr) Gene codant pour un activateur de l&#39;endoglycoceramidase
EP0669396A4 (fr) Nouveau polypeptide et adn codant pour celui-ci.
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
CA2245584A1 (fr) Expression par recombinaison de proteines de couche superficielle
WO1996038556A3 (fr) Deltap62, ses variants, sequences d&#39;acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse
AU6063900A (en) Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU1137699A (en) Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor
AU1440695A (en) P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof
AU5627090A (en) A novel alpha-amylase-pullulanase enzyme, a dna sequence coding the same, a recombinant dna molecule and a recombinant clone expressing the enzyme
AU6260796A (en) Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AU2035295A (en) Gene encoding cationic amino acid transporter protein
WO1997029194A3 (fr) Preparation d&#39;acide l-ascorbique
AU5455798A (en) Gene product over expressed in cancer cells
WO1999031229A3 (fr) Peptides et acides nucleiques derives d&#39;eisenia foetida et leur utilisation
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/008877

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2219861

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2219861

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08952899

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV1997-3759

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 161397

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1996 536252

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996918728

Country of ref document: EP

Ref document number: 1019970708672

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1997-3759

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996918728

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970708672

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1997-3759

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1996918728

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970708672

Country of ref document: KR